Morningstar Investment Management LLC Has $2.22 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Morningstar Investment Management LLC lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 57.6% in the first quarter, Holdings Channel.com reports. The firm owned 24,537 shares of the medical equipment provider’s stock after selling 33,328 shares during the period. Morningstar Investment Management LLC’s holdings in Zimmer Biomet were worth $2,219,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. DV Equities LLC purchased a new stake in Zimmer Biomet in the 4th quarter worth about $25,000. Monetary Solutions Ltd purchased a new position in Zimmer Biomet during the 4th quarter valued at about $30,000. Gen Wealth Partners Inc acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at about $31,000. Flagship Harbor Advisors LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at about $32,000. Finally, Headlands Technologies LLC purchased a new stake in shares of Zimmer Biomet in the second quarter worth approximately $37,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.28% of the stock is currently owned by company insiders.

Zimmer Biomet Price Performance

NYSE ZBH opened at $91.35 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $17.67 billion, a PE ratio of 23.73, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29. The company has a 50 day moving average price of $87.90 and a two-hundred day moving average price of $89.81.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ZBH. Robert W. Baird set a $92.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 target price on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Barclays decreased their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research note on Wednesday, April 29th. Stifel Nicolaus dropped their price target on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. Finally, Leerink Partners started coverage on Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $100.70.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.